Navigation Links
First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
Date:2/13/2008

ATLANTA, Feb. 13 /PRNewswire/ -- On Thursday, January 31, General Hospital Vienna successfully completed its first Volumetric Modulated Arc Therapy (VMAT)* treatment. The hospital is one of the first in the world to carry out this innovative cancer treatment option.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )

VMAT technology provides a simultaneous control of the linear accelerator gantry position and speed, the leaves and angle of the multileaf collimator and dose rate. This flexibility enables highly conformal cancer treatments, as well as optimal sparing of the healthy tissue around the target. In addition, VMAT significantly reduces patient treatment times, leading to greater patient comfort and stillness for a more efficient and precise treatment.

Dietmar Georg, Ph.D., head of the Division of Medical Radiation Physics at General Hospital Vienna (Medical University Vienna, Vienna, Austria) says the first patient was treated for glioblastoma, a serious brain tumor that was positioned near vital structures such as the brain stem and optical lenses and nerves. The treatment consisted of three non-coplanar VMAT arcs with collimator rotation. The entire treatment took just 10 minutes, including creation and evaluation of the patient's brain images and treatment positioning.

"This therapy is applied in very complex situations where the localization and form of the tumor requires tailored intensity modulated treatment," says Dr. Georg.

Elekta provides complete VMAT package

General Hospital Vienna used its existing Elekta Synergy(R) S system to perform the VMAT treatment, along with Elekta's next generation linear accelerator control software. Elekta's VMAT solution also includes ERGO++ treatment planning system for rotational therapy, and MOSAIQ(TM) image-enabled oncology Electronic Medical Records (EMR) system. This
'/>"/>

SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, 2014, the ... Industrial Average finished the day 0.42% lower at 16,915.07, and ... were broad based as eight out of ten sectors ended ... Index ended the day at 711.88, down 0.02%, while the ... has initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... , , , Funding and ... NEW YORK, Dec. 14 The Microbicides Development Programme announced ... conducted among almost 9,400 women in four African countries, found ... of HIV infection. , Reacting to today,s announcement, AVAC executive ...
... InterMune, Inc. (Nasdaq: ITMN ) today announced that Steve ... the 2009 DB-Biotech Boston Confab on December 15, 2009 at ... audio webcast of the presentation, investors and other interested parties ... corporate website at www.intermune.com. The company recommends logging on ...
Cached Medicine Technology:AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 2AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 3
(Date:7/13/2014)... Ticket Down is a reliable source ... For the fifth straight year (and second under the current ... American stadiums this summer. The tournament features eight club teams ... teams are split into two groups of four and upon ... will compete to become champion. One team that has had ...
(Date:7/13/2014)... Nature Genetics identifies a novel genetic ... eosinophillic esophagitis (EoE), opening up potential new therapeutic ... , EoE is a chronic inflammatory disorder ... allergic hypersensitivity to certain foods and an over-accumulation ... eosinophils (part of the body,s immune system). EoE ...
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from ... . Additionally, the company’s chief executive officer has announced a ... caskets are offered at discounted prices, from 15 to 26 ... caskets are in huge demand in the current market. We ... We have a lot of high quality products for sale. ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized ... as wells as to maintain soil quality. The application ... become a dominant revenue generator for manufacturers in future. ... resource costs has led to the adoption of micro ... further caused massive demand for micro irrigation systems, as ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Fuel additives ... as gasoline, diesel, jet fuel, kerosene, and so on, ... also responsible for reducing the corrosion effects caused by ... when added to any fuel, provide economies of scale ... these escalate the overall cost of the fuel products. ...
Breaking Medicine News(10 mins):Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4
... The chances of infection are boosted 50-fold to 100,000-fold, study ... discovery that perplexes HIV experts, an international team reports that ... of the virus to do its damage. , According to ... , the fibers capture the virus and then ferry it ...
... this dependence could stop disease before it starts , ... growth factors contributes to the development of cancers caused ... a normally silent gene, scientists say. , The team ... addiction might help prevent cancer growth. , They ...
... eye also detects light for a number of non-visual phenomena. ... sleep/wake cycle, which is synchronized by the effects of light ... a study published online on December 13th in Current Biology, ... to light remain intact, suggesting that visual and non-visual responses ...
... Dec. 13 A letter recently sent to,presidential ... according to groups representing full-service community hospitals.,Those groups, ... Hospital,Association (AHA), sent their own letter to the ... impact of limited-service facilities, which,drive up the nation,s ...
... to common ... antibiotic treatment, BERKELEY SPRINGS, W.Va., ... sprays provide little,to no relief of symptoms associated with sinus infections. ... they,took antibiotics, steroids, or placebos., One such study appears in ...
... Extend Product Offering to Healthcare Customers, DALLAS, ... leading provider of electronic transaction services to the,Healthcare ... an agreement,to acquire substantially all the assets of ... is subject to due diligence and is structured,as ...
Cached Medicine News:Health News:Fibers in Semen Help HIV Penetrate Cells 2Health News:Cell 'Addiction' to Growth Factors May Help Spur Cancers 2Health News:Blind humans lacking rods and cones retain normal responses to non-visual effects of light 2Health News:Blind humans lacking rods and cones retain normal responses to non-visual effects of light 3Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 2Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 3Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 4Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 5Health News:31 Million Americans Suffer From Sinus Infections 2Health News:Claimsnet to Acquire Acceptius 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Medicine Products: